http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Patent strategy in pharmaceutical industry
Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20.
Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.
Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
Baden-Baden : Nomos Verlagsgesellschaft, ©2014